Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
=== Southeast Asia === Soybeans were mentioned as kadêlê (modern Indonesian term: kedelai) in an old Javanese manuscript, Serat Sri Tanjung, which dates to 12th- to 13th-century Java. By the 13th century, the soybean had arrived and cultivated in Indonesia; it probably arrived much earlier however, carried by traders or merchants from Southern China. The earliest known reference to it as "tempeh" appeared in 1815 in the Serat Centhini manuscript. The development of tempeh fermented soybean cake probably took place earlier, circa 17th century in Java.
It’s a fight for our national security." He advocated for a special inspector general to monitor the aid given to Ukraine following Russia's invasion. Kennedy expressed concern that money was being misspent, saying, "Ukraine is not without flaws. We've heard several unsettling reports of bad actors exploiting our generosity… We trust that our friends in Ukraine take corruption seriously. We must verify, too."
In the spring of 1778, a heavy chain supported by huge log rafts was stretched across the Hudson from West Point to Constitution Island to impede the movement of British ships north of West Point. A second log boom (resembling a ladder in construction) spanned the river about 100 yards (90 m) downstream to absorb the impact of any ship attempting to breach the barrier. The Hudson River's changing tides, strong current, and frequently unfavorable winds created adverse sailing conditions at West Point. Compounding this, the river's narrow width and sharp "S-Curve" there forced any large ship to tack in order to navigate it. Cannon were placed in forts and artillery batteries on both sides of the river to attack ships when they were slowed to a halt by the Patriot barrier placed there. The chain was constructed over six weeks at the Sterling Iron Works in Warwick, Orange County. The multiple forge-fire site and trip hammer was rediscovered in 2008 within Sterling Forest State Park. When completed, the 600-yard (550 m) chain contained iron links two feet (0.6 m) in length, weighing 140 to 180 pounds (64 to 82 kg). The links were carted to New Windsor, where they were put together and floated down the river to West Point on logs late in April. Including swivels, clevises, and anchors, the chain weighed 65 tons. For buoyancy, logs were cut into 16-foot (5 m) lengths, waterproofed, and joined by fours into rafts fastened to one another with 12-foot (3.7 m) timbers.
Sources: en.wikipedia.org
This principle of self-determination had been declared on numerous occasions subsequent to the declaration – President Wilson's January 1918 Fourteen Points, Sykes's Declaration to the Seven in June 1918, the November 1918 Anglo-French Declaration, and the June 1919 Covenant of the League of Nations that had established the mandate system. In an August 1919 memo Balfour acknowledged the inconsistency among these statements, and further explained that the British had no intention of consulting the existing population of Palestine. The results of the ongoing American King–Crane Commission of Enquiry consultation of the local population – from which the British had withdrawn – were suppressed for three years until the report was leaked in 1922. Subsequent British governments have acknowledged this deficiency, in particular the 1939 committee led by the Lord Chancellor, Frederic Maugham, which concluded that the government had not been "free to dispose of Palestine without regard for the wishes and interests of the inhabitants of Palestine", and the April 2017 statement by British Foreign Office minister of state Baroness Anelay that the government acknowledged that "the Declaration should have called for the protection of political rights of the non-Jewish communities in Palestine, particularly their right to self-determination."
He noted its use in Ancient Rome in religious ceremonies to purify homes by fumigation (something also briefly evoked in a line of Ovid's Ars Amatoria about purifying houses with eggs and sulfur). The use of sulfur for fumigation is very ancient and was already a practice in preclassical Greece; this is mentioned in the Odyssey. Several Roman authors of the second half of the first century, such as Martial and Statius, reference a type of street trade seemingly common at the time, where peddlers in the streets would exchange pieces of sulfur or sulfur "matches" (actually some kind of sulfured wooden splints used as a fire starter, rather than friction matches) for broken glass. The Persian army used sulfur as a chemical weapon during the siege of Dura-Europos, in the 3rd century. They burned pitch and sulfur in tunnels, creating a toxic cloud of sulfur dioxide which killed the Roman soldiers in the tunnels. A natural form of sulfur known as shiliuhuang (Chinese: 石硫黃; pinyin: shí liú huáng) was known in China since the 6th century BC and found in Hanzhong. By the 3rd century, the Chinese had discovered that sulfur could be extracted from pyrite. Chinese Daoists were interested in sulfur's flammability and its reactivity with certain metals, yet its earliest practical uses were found in traditional Chinese medicine.
=== Evolution and resistance === Due to the high mutation rates of retroviruses, especially due to mutationally sensitive regions (notably the region containing the catalytic triad sequence), and considering that changes to a few amino acids within HIV protease can render it much less visible to an inhibitor, the residues at the active site of this enzyme can change rapidly when under the selective pressure of replication-inhibiting drugs. Despite most of known resistant mutations that can affect the stability of the HIV-1 PR, the protein could still perform its catalytic activity, sometimes facilitated by compensatory mutations. Two types of mutations are generally associated with increasing drug resistance: "major" mutations and "secondary" mutations. Major mutations involve a mutation on the active site of HIV-1 PR, preventing the selective inhibitors from binding it. Secondary mutations refer to molecular changes on the periphery of the enzyme due to prolonged exposure to similar chemicals, potentially affecting inhibitor specificity for HIV-1 PR. One approach to minimizing the development of drug-resistance in HIV is to administer a combination of drugs which inhibit several key aspects of the HIV replication cycle simultaneously, rather than one drug at a time. Other drug therapy targets include reverse transcriptase, virus attachment, membrane fusion, cDNA integration and virion assembly.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.